Precautions concerning the use of theophylline

R. E. Kauffman, W. Banner, C. Berlin, J. L. Blumer, R. L. Gorman, G. H. Lambert, G. S. Wilson, D. R. Bennett, J. F. Cordero, Paul G Tomich, S. A. Licata, P. Kaufman, G. Troendle, S. J. Yaffe, C. J. Cote, M. E. Mortensen, W. Snodgrass, A. R. Temple, S. J. Szefler

Research output: Contribution to journalComment/debate

11 Citations (Scopus)

Abstract

1. Theophylline continues to be an important adjunct in the management of reactive airway diseases and central apnea in pediatric patients. 2. Theophylline metabolism may be reduced in the presence of acute febrile illnesses and certain concurrently administered medications which inhibit the ophylline metabolism, thereby increasing the risk of toxicity if the dose is not reduced. 3. The dose of theophylline should be reduced by one half in patients who are febrile for longer than 24 hours. Further dose adjustments should be based on serum concentration monitoring until the patients have recovered from their acute illness and are restabilized on their usual dosages. 4. The concurrent administration of drugs which interfere with theophylline metabolism (Table) should be avoided. If concurrent use is necessary, the dose of theophylline should be decreased by one half and subsequently adjusted based on serum concentration monitoring. 5. It is advisable to check the serum theophylline concentration within 24 hours after beginning any new concurrently administered medication for which there is no specific information regarding interactions with theophylline.

Original languageEnglish (US)
Pages (from-to)781-783
Number of pages3
JournalPediatrics
Volume89
Issue number4 SUPPL.
StatePublished - Jan 1 1992

Fingerprint

Theophylline
Fever
Serum
Central Sleep Apnea
Airway Management
Physiologic Monitoring
Pediatrics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Kauffman, R. E., Banner, W., Berlin, C., Blumer, J. L., Gorman, R. L., Lambert, G. H., ... Szefler, S. J. (1992). Precautions concerning the use of theophylline. Pediatrics, 89(4 SUPPL.), 781-783.

Precautions concerning the use of theophylline. / Kauffman, R. E.; Banner, W.; Berlin, C.; Blumer, J. L.; Gorman, R. L.; Lambert, G. H.; Wilson, G. S.; Bennett, D. R.; Cordero, J. F.; Tomich, Paul G; Licata, S. A.; Kaufman, P.; Troendle, G.; Yaffe, S. J.; Cote, C. J.; Mortensen, M. E.; Snodgrass, W.; Temple, A. R.; Szefler, S. J.

In: Pediatrics, Vol. 89, No. 4 SUPPL., 01.01.1992, p. 781-783.

Research output: Contribution to journalComment/debate

Kauffman, RE, Banner, W, Berlin, C, Blumer, JL, Gorman, RL, Lambert, GH, Wilson, GS, Bennett, DR, Cordero, JF, Tomich, PG, Licata, SA, Kaufman, P, Troendle, G, Yaffe, SJ, Cote, CJ, Mortensen, ME, Snodgrass, W, Temple, AR & Szefler, SJ 1992, 'Precautions concerning the use of theophylline', Pediatrics, vol. 89, no. 4 SUPPL., pp. 781-783.
Kauffman RE, Banner W, Berlin C, Blumer JL, Gorman RL, Lambert GH et al. Precautions concerning the use of theophylline. Pediatrics. 1992 Jan 1;89(4 SUPPL.):781-783.
Kauffman, R. E. ; Banner, W. ; Berlin, C. ; Blumer, J. L. ; Gorman, R. L. ; Lambert, G. H. ; Wilson, G. S. ; Bennett, D. R. ; Cordero, J. F. ; Tomich, Paul G ; Licata, S. A. ; Kaufman, P. ; Troendle, G. ; Yaffe, S. J. ; Cote, C. J. ; Mortensen, M. E. ; Snodgrass, W. ; Temple, A. R. ; Szefler, S. J. / Precautions concerning the use of theophylline. In: Pediatrics. 1992 ; Vol. 89, No. 4 SUPPL. pp. 781-783.
@article{70d35c6e8d2b45dcb5690d90006a9799,
title = "Precautions concerning the use of theophylline",
abstract = "1. Theophylline continues to be an important adjunct in the management of reactive airway diseases and central apnea in pediatric patients. 2. Theophylline metabolism may be reduced in the presence of acute febrile illnesses and certain concurrently administered medications which inhibit the ophylline metabolism, thereby increasing the risk of toxicity if the dose is not reduced. 3. The dose of theophylline should be reduced by one half in patients who are febrile for longer than 24 hours. Further dose adjustments should be based on serum concentration monitoring until the patients have recovered from their acute illness and are restabilized on their usual dosages. 4. The concurrent administration of drugs which interfere with theophylline metabolism (Table) should be avoided. If concurrent use is necessary, the dose of theophylline should be decreased by one half and subsequently adjusted based on serum concentration monitoring. 5. It is advisable to check the serum theophylline concentration within 24 hours after beginning any new concurrently administered medication for which there is no specific information regarding interactions with theophylline.",
author = "Kauffman, {R. E.} and W. Banner and C. Berlin and Blumer, {J. L.} and Gorman, {R. L.} and Lambert, {G. H.} and Wilson, {G. S.} and Bennett, {D. R.} and Cordero, {J. F.} and Tomich, {Paul G} and Licata, {S. A.} and P. Kaufman and G. Troendle and Yaffe, {S. J.} and Cote, {C. J.} and Mortensen, {M. E.} and W. Snodgrass and Temple, {A. R.} and Szefler, {S. J.}",
year = "1992",
month = "1",
day = "1",
language = "English (US)",
volume = "89",
pages = "781--783",
journal = "Pediatrics",
issn = "0031-4005",
publisher = "American Academy of Pediatrics",
number = "4 SUPPL.",

}

TY - JOUR

T1 - Precautions concerning the use of theophylline

AU - Kauffman, R. E.

AU - Banner, W.

AU - Berlin, C.

AU - Blumer, J. L.

AU - Gorman, R. L.

AU - Lambert, G. H.

AU - Wilson, G. S.

AU - Bennett, D. R.

AU - Cordero, J. F.

AU - Tomich, Paul G

AU - Licata, S. A.

AU - Kaufman, P.

AU - Troendle, G.

AU - Yaffe, S. J.

AU - Cote, C. J.

AU - Mortensen, M. E.

AU - Snodgrass, W.

AU - Temple, A. R.

AU - Szefler, S. J.

PY - 1992/1/1

Y1 - 1992/1/1

N2 - 1. Theophylline continues to be an important adjunct in the management of reactive airway diseases and central apnea in pediatric patients. 2. Theophylline metabolism may be reduced in the presence of acute febrile illnesses and certain concurrently administered medications which inhibit the ophylline metabolism, thereby increasing the risk of toxicity if the dose is not reduced. 3. The dose of theophylline should be reduced by one half in patients who are febrile for longer than 24 hours. Further dose adjustments should be based on serum concentration monitoring until the patients have recovered from their acute illness and are restabilized on their usual dosages. 4. The concurrent administration of drugs which interfere with theophylline metabolism (Table) should be avoided. If concurrent use is necessary, the dose of theophylline should be decreased by one half and subsequently adjusted based on serum concentration monitoring. 5. It is advisable to check the serum theophylline concentration within 24 hours after beginning any new concurrently administered medication for which there is no specific information regarding interactions with theophylline.

AB - 1. Theophylline continues to be an important adjunct in the management of reactive airway diseases and central apnea in pediatric patients. 2. Theophylline metabolism may be reduced in the presence of acute febrile illnesses and certain concurrently administered medications which inhibit the ophylline metabolism, thereby increasing the risk of toxicity if the dose is not reduced. 3. The dose of theophylline should be reduced by one half in patients who are febrile for longer than 24 hours. Further dose adjustments should be based on serum concentration monitoring until the patients have recovered from their acute illness and are restabilized on their usual dosages. 4. The concurrent administration of drugs which interfere with theophylline metabolism (Table) should be avoided. If concurrent use is necessary, the dose of theophylline should be decreased by one half and subsequently adjusted based on serum concentration monitoring. 5. It is advisable to check the serum theophylline concentration within 24 hours after beginning any new concurrently administered medication for which there is no specific information regarding interactions with theophylline.

UR - http://www.scopus.com/inward/record.url?scp=0026528576&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026528576&partnerID=8YFLogxK

M3 - Comment/debate

VL - 89

SP - 781

EP - 783

JO - Pediatrics

JF - Pediatrics

SN - 0031-4005

IS - 4 SUPPL.

ER -